ISIN | LU0329631708 |
---|---|
Valor Number | 3535030 |
Bloomberg Global ID | VARMVI2 LX |
Fund Name | Variopartner SICAV - MIV Global Medtech Fund I2 |
Fund Provider |
MIV Global Medtech Fund
Feldeggstrasse 55 8008 Zürich Schweiz Phone: +41 44 253 64 11 E-Mail: info@mivam.ch |
Fund Provider | MIV Global Medtech Fund |
Representative in Switzerland |
Vontobel Fonds Services AG Zürich Phone: +41 58 283 74 77 |
Distributor(s) |
Vontobel Fonds Services AG Zürich Phone: +41 58 283 74 77 |
Asset Class | Equities |
EFC Category | Equity Health Care |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund does not charge any issuing commission and/or fees (units are issued at the NAV) |
Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
Investment Strategy *** | This Sub-Fund aims to achieve maximum capital growth by means of investments in the sector of medical technology worldwide. In order to achieve this, and taking account of the principle of risk diversification, a minimum of two-thirds of the SubFund’s total assets are invested directly in equities, equity-like transferable securities, participation certificates, depositary receipts, such as American Depositary Receipts (ADRs), Global Depositary Receipts (GDRs) and European Depositary Receipts (EDRs) referring to such securities, etc. from issuers worldwide, mainly active in the sector of medical technology. Besides this, up to one third of the total assets of the Sub-Fund may be invested in participation securities from companies that are not or not principally active in the sector of medical technology. |
Peculiarities |
Current Price * | 3,149.91 EUR | 04.02.2025 |
---|---|---|
Previous Price * | 3,168.92 EUR | 03.02.2025 |
52 Week High * | 3,173.89 EUR | 30.01.2025 |
52 Week Low * | 2,572.92 EUR | 05.08.2024 |
NAV * | 3,149.91 EUR | 04.02.2025 |
Issue Price * | 3,149.91 EUR | 04.02.2025 |
Redemption Price * | 3,149.91 EUR | 04.02.2025 |
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 2,209,878,624 | |
Unit/Share Assets *** | 317,069,996 | |
Trading Information SIX |
YTD Performance | +8.57% |
31.12.2024 - 04.02.2025
31.12.2024 04.02.2025 |
---|---|---|
YTD Performance (in CHF) | +8.53% |
31.12.2024 - 04.02.2025
31.12.2024 04.02.2025 |
1 month | +7.68% |
06.01.2025 - 04.02.2025
06.01.2025 04.02.2025 |
3 months | +11.91% |
04.11.2024 - 04.02.2025
04.11.2024 04.02.2025 |
6 months | +22.43% |
05.08.2024 - 04.02.2025
05.08.2024 04.02.2025 |
1 year | +16.87% |
05.02.2024 - 04.02.2025
05.02.2024 04.02.2025 |
2 years | +26.04% |
06.02.2023 - 04.02.2025
06.02.2023 04.02.2025 |
3 years | +18.32% |
04.02.2022 - 04.02.2025
04.02.2022 04.02.2025 |
5 years | +36.24% |
04.02.2020 - 04.02.2025
04.02.2020 04.02.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | 0.0626 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date | 04.02.2025 |
Boston Scientific Corp | 9.91% | |
---|---|---|
Abbott Laboratories | 9.89% | |
Intuitive Surgical Inc | 9.84% | |
Stryker Corp | 9.58% | |
Medtronic PLC | 4.60% | |
Essilorluxottica | 4.58% | |
Alcon Inc | 4.23% | |
Edwards Lifesciences Corp | 4.21% | |
Becton Dickinson & Co | 4.14% | |
Hoya Corp | 3.90% | |
Last data update | 31.12.2024 |
TER | 0.97% |
---|---|
TER date | 28.06.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 0.90% |
Ongoing Charges *** | 0.97% |
SRRI ***
|
|
SRRI date *** | 31.12.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |